Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
2019-nCoV Inactivated Vaccine group:Nil
non vaccinated group:Nil
Sponsors
Chongqing General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: 1.Healthy subjects aged 18-59 years; 2.Gender: male or non-pregnant or non-lactating female; 3.No history of major diseases, history of drug allergy and vaccination Allergy history; 4.No history of new coronary pneumonia or infection history, holding a health code "green code"; 5.Able to complete the two-month clinical research follow-up.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic to any component of the vaccine, and those who have had severe allergic reactions to the vaccine in the past (such as anaphylactic shock, acute allergic reactions, urticaria, skin eczema, dyspnea, angioedema or abdominal pain); 2. Sufferers Acute disease, severe chronic disease, acute onset of chronic disease, and fever; 3. Pregnant women and lactating women, those who have a childbirth plan within 3 months of vaccination; 4. Have a history or family history of convulsions, epilepsy, encephalopathy or mental illness; suffer from uncontrolled epilepsy and other progressive neurological diseases Those with a history of Guillain-Barre syndrome; 5. Those who have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases; 6. Known or suspected Patients with severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases, and malignant tumors; 7. Those who use immunosuppressive drugs such as anti-tumor drugs; 8. Those who suffer from thrombocytopenia or bleeding disorders; 9. Clinicians Or the vaccination staff believes that they are not suitable for vaccination against the COVID-19.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2019-nCoV related antibodies;Cytokines;Serum peptide fingerprint;Proportion of T lymphocyte subsets;CD4/CD8 ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| Immune factor;Proteomics molecular profiling;Metabolomics molecular profiling; | — |
Countries
China
Contacts
Public ContactLiao Pu
Chongqing General Hospital
Outcome results
None listed